GMED:NYSEGlobus Medical, Inc. Analysis

Globus Medical delivered a revenue surge of 25.7% YoY in Q4 CY2025, topping consensus estimates and pushing full‑year guidance to $3.2 billion, a modest 1.2% beat. Margins are healthy, with a gross margin of 68% and an operating margin of 24.4%, while EPS climbed to $3.92 trailing and is projected at $4.96 forward, underscoring robust earnings momentum. Valuation metrics reinforce the upside narrative: the stock trades at a P/E of 22.4, below the industry average of 25.7, and the DCF model assigns a fair value of $92.94, implying roughly a 25% upside from the current $87.92 price. The technical backdrop is supportive – the MACD histogram turned positive, the RSI sits near a neutral 51, volume is on an increasing trend, and price is comfortably above the $82 support while approaching a $90.4 resistance.
Risk considerations are tempered by a beta of ~1 and a 30‑day volatility of 30%, indicating market‑aligned price swings but no extreme beta exposure. The sector’s regulatory environment is moderate, and the company’s balance sheet is strong with ample cash and modest debt, reducing liquidity concerns. Combined with a Zacks Rank 1 “Strong Buy” upgrade and favorable analyst sentiment, the overall outlook favors a buy stance across horizons.